pteridines has been researched along with Arachnoidal Cerebellar Sarcoma, Circumscribed in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We here assessed the therapeutic efficacy of the orally bioavailable BRD4 inhibitor, MK-8628, in preclinical models of medulloblastoma." | 5.51 | Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. ( Althoff, K; Bei, Y; Deubzer, HE; Eggert, A; Garcia, HD; Han, Y; Henssen, AG; Künkele, A; Lindner, S; Lissat, A; Odersky, A; Schramm, A; Schulte, JH; Timme, N, 2019) |
| "These findings support the further exploration of volasertib for pediatric malignancies, particularly alveolar rhabdomyosarcoma, and its combination with mitotic spindle poison." | 3.83 | Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies. ( Abbou, S; Daudigeos-Dubus, E; Geoerger, B; Lanvers-Kaminsky, C; Laplace-Builhe, C; LE Dret, L; Molenaar, J; Vassal, G, 2016) |
| " We here assessed the therapeutic efficacy of the orally bioavailable BRD4 inhibitor, MK-8628, in preclinical models of medulloblastoma." | 1.51 | Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. ( Althoff, K; Bei, Y; Deubzer, HE; Eggert, A; Garcia, HD; Han, Y; Henssen, AG; Künkele, A; Lindner, S; Lissat, A; Odersky, A; Schramm, A; Schulte, JH; Timme, N, 2019) |
| "Medulloblastoma is the most common malignant brain tumor in children." | 1.39 | Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. ( Berns, R; Bouffet, E; Dunham, C; Dunn, SE; Foster, C; Fotovati, A; Hawkins, C; Hukin, J; Lee, C; Manoranjan, B; Narendran, A; Northcott, P; O'Halloran, K; Pambid, MR; Ramaswamy, V; Rassekh, R; Singh, SK; Singhal, A; Taylor, MD; Triscott, J; Venugopal, C; Yip, S, 2013) |
| "Medulloblastoma is the most common malignant brain tumor in children and remains a therapeutic challenge due to its significant therapy-related morbidity." | 1.38 | Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. ( Alimova, I; Birks, DK; Donson, AM; Dubuc, A; Foreman, NK; Handler, MH; Harris, PS; Knipstein, J; Taylor, MD; Venkataraman, S; Vibhakar, R, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, Y | 1 |
| Lindner, S | 1 |
| Bei, Y | 1 |
| Garcia, HD | 1 |
| Timme, N | 1 |
| Althoff, K | 1 |
| Odersky, A | 1 |
| Schramm, A | 1 |
| Lissat, A | 1 |
| Künkele, A | 1 |
| Deubzer, HE | 1 |
| Eggert, A | 1 |
| Schulte, JH | 1 |
| Henssen, AG | 1 |
| Pambid, MR | 2 |
| Berns, R | 2 |
| Adomat, HH | 1 |
| Hu, K | 1 |
| Triscott, J | 2 |
| Maurer, N | 1 |
| Zisman, N | 1 |
| Ramaswamy, V | 2 |
| Hawkins, CE | 1 |
| Taylor, MD | 3 |
| Dunham, C | 2 |
| Guns, E | 1 |
| Dunn, SE | 2 |
| Lee, C | 1 |
| Foster, C | 1 |
| Manoranjan, B | 1 |
| Fotovati, A | 1 |
| Venugopal, C | 1 |
| O'Halloran, K | 1 |
| Narendran, A | 1 |
| Hawkins, C | 1 |
| Bouffet, E | 1 |
| Singhal, A | 1 |
| Hukin, J | 1 |
| Rassekh, R | 1 |
| Yip, S | 1 |
| Northcott, P | 1 |
| Singh, SK | 1 |
| Abbou, S | 1 |
| Lanvers-Kaminsky, C | 1 |
| Daudigeos-Dubus, E | 1 |
| LE Dret, L | 1 |
| Laplace-Builhe, C | 1 |
| Molenaar, J | 1 |
| Vassal, G | 1 |
| Geoerger, B | 1 |
| Harris, PS | 1 |
| Venkataraman, S | 1 |
| Alimova, I | 1 |
| Birks, DK | 1 |
| Donson, AM | 1 |
| Knipstein, J | 1 |
| Dubuc, A | 1 |
| Handler, MH | 1 |
| Foreman, NK | 1 |
| Vibhakar, R | 1 |
5 other studies available for pteridines and Arachnoidal Cerebellar Sarcoma, Circumscribed
| Article | Year |
|---|---|
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Topics: Acetanilides; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Dr | 2019 |
Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cerebellar Neoplasms; Child; Chromatogr | 2014 |
Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
Topics: Adolescent; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Cycle Proteins; Child; Child, Pres | 2013 |
Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Neoplasm | 2016 |
Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
Topics: Apoptosis; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cerebellar | 2012 |